drugset

drugset / Trial / NCT00568035

Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

NCT00568035 ↗

Phase 2 Completed 140 enrolled Quigley Pharma, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether QR-333 is safe and effective in the treatment of diabetic neuropathy as compared to placebo.

Timeline

Start: 2006-12
Primary completion: 2008-11
Completion: 2008-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	QR-333	Unknown	—	Topical

Indications